Transdermal device containing microneedles

• US 8,636,696 B2
• Filed: 06/10/2011
• Issued: 01/28/2014
• Est. Priority Date: 06/10/2011
• Status: Active Grant

• Current Assignee: Sorrento Therapeutics Inc.
• Original Assignee: Kimberly-Clark Worldwide Incorporated (Kimberly-Clark Corporation)
• Inventors: Ross, Russell Frederick, Baker, Andrew
• Primary Examiner(s): Sirmons, Kevin C
• Assistant Examiner(s): LEE, BRANDY SCOTT
• Application Number:
  US13/157,412
• Publication Number:
  US 20120316503A1
• Time in Patent Office: 963 Days
• Field of Search: 604/173, 604/272, 604/93.01, 604/264, 606/167, 606/172, 606/181, 606/183, 606184-185
• US Class Current: 604/173
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0038 having a channel at the side surface
• CPC Class Codes: A61M 37/0015 by using microneedles

Abstract

The present invention includes a microneedle assembly having a support that includes a first surface and a second surface, the second surface further including a slanted surface. A plurality of microneedles are provided which project outwardly from the second surface of the support. A pathway through the microneedle assembly is formed and includes an aperture extending between the first surface of the support and the second surface of the support, a channel disposed on the exterior surface of at least one microneedle, the channel having a surface, the channel being in alignment with at least a portion of the aperture to form a junction through which fluids may pass.

Claims

1. A microneedle assembly comprising:

a support comprising a first outer surface and a second outer surface, the second outer surface having sections that are parallel and sections that are slanted relative to the first surface;

a plurality of microneedles projecting outwardly from the second outer surface of the support, the microneedles comprising a base, a tip and an exterior surface;

a pathway comprising

an aperture extending through the interior of the support between the first outer surface of the support and the second outer surface of the support;

a channel disposed on the exterior surface of the plurality of microneedles, the channel having a surface, the channel being in end-to-end alignment with at least a portion of the aperture to form a junction through which fluids may pass, the junction being formed in the plane of the slanted section of the second outer surface of the support proximate to the base of the microneedle; and

a first angle formed between the slanted section of the second outer surface and the surface of the channel, the first angle being greater than 90 degrees.

2. The microneedle assembly as claimed in claim 1, the first angle being less than 160 degrees.

3. The microneedle assembly as claimed in claim 1, the first angle being greater than 110 degrees.

4. The microneedle assembly as claimed in claim 1, the first angle being greater than 120 degrees.

5. The microneedle assembly as claimed in claim 4, the first angle being greater than 135 degrees.

6. The microneedle assembly as claimed in claim 1, wherein the plurality of microneedles have at least two channels on the exterior surface.

7. The microneedle assembly as claimed in claim 1, the channel forming a non-linear path on the exterior surface of the microneedle.

8. The transdermal delivery device of claim 1 wherein the base of the microneedle is cylindrical or rectangular in shape.

9. The transdermal delivery device of claim 8 wherein the tip of the microneedle has a conical or pyramidal shape.

10. The transdermal delivery device of claim 1 wherein the cross-sections of the apertures and channels are coextensive at the junctions and further wherein the fluidic pathways comprise a linear pathway.

11. The transdermal delivery device of claim 1 wherein the junctions associated with at least two distinct microneedles are formed in the plane of a single continuous slanted section of the second outer surface of the support.

12. A transdermal drug delivery device comprising:

(i) a microneedle assembly comprising,

(a) a support comprising a first outer surface and a second outer surface, the second outer surface having sections that are parallel and sections that are slanted relative to the first outer surface;

(b) a plurality of microneedles projecting outwardly from the second outer surface of the support, the microneedles comprising a base, a tip and an exterior surface;

(c) fluidic pathways comprising

a plurality of apertures extending through the interior of the support between the first outer surface of the support and the second outer surface of the support,

at least one channel disposed on the exterior surface of at least one microneedle, the channel having a surface, the channel being in end-to-end alignment with at least a portion of one of said apertures to form a junction through which fluids may pass, the junction being formed in the plane of the slanted section of the second outer surface of the support proximate to the base of the microneedles wherein a first angle formed between the slanted section of the second surface and the surface of the channel is greater than 90 degrees;

(ii) a drug delivery assembly comprising

(a) a reservoir for holding a drug compound,

(b) a rate control membrane that is in fluid communication with the reservoir positioned between the reservoir and the first outer surface of the support, and

(iii) a release member that is impermeable to the drug compound and positioned adjacent to the rate control membrane of the drug delivery assembly and the first surface of the support of the microneedle assembly, wherein the release member is configured to be at least partially separated from the rate control membrane of the drug delivery assembly and the support of the microneedle assembly when drug delivery device is an active configuration.

13. The transdermal drug delivery device of claim 12, wherein the drug delivery assembly further comprises an adhesive layer, the reservoir being positioned between the adhesive layer and the rate control membrane.

14. The transdermal drug delivery device of claim 12, wherein the release member is positioned between the rate control membrane and the support.

15. The transdermal drug delivery device as claimed in claim 12, the first angle being less than 160 degrees.

16. The transdermal drug delivery device as claimed in claim 12, wherein the microneedles have at least two channels.

17. The transdermal drug delivery device as claimed in claim 12, the channel forming a non-linear path on the exterior surface of the microneedle.

18. The transdermal delivery device as claimed in claim 12, the first angle being greater than 110 degrees.

19. The transdermal delivery device of claim 12 wherein the rate control membrane comprises a porous material having an average pore size of between about 50 nanometers to about 5 micrometers.

20. The transdermal delivery device of claim 12 wherein the release member has an exposed tab that extends at least partly beyond the perimeter of the microneedle assembly and further wherein the release member is configured to be at least partially separated from the rate control membrane of the drug delivery assembly and the support of the microneedle assembly when the exposed tab of the release member is pulled.